Role of Microparticles Derived from Monocytes, Endothelial Cells and Platelets in the Exacerbation of COPD

Overview

Journal Int J Chron Obstruct Pulmon Dis

Publisher Dove Medical Press

Specialty Pulmonary Medicine

Date 2018 Dec 12

PMID 30532530

Citations 9

Authors

Margit Tokes-Fuzesi

Istvan Ruzsics

Orsolya Rideg

Peter Kustan

Gabor L Kovacs

Tihamer Molnar

Affiliations

Soon will be listed here.

Abstract

Background: Microparticles (MPs) are shedding membrane vesicles released from activated blood and endothelial cells under inflammatory conditions. The role of endothelial MPs (EMPs) in pathophysiology of COPD is relatively well known. However, the release and function of MPs of other cellular origins, eg, platelets, red blood cells and leukocytes, are not clearly evaluated in COPD.

Purpose: The aim of this study was to measure EMPs and other cell-derived circulating MPs in stable and exacerbated COPD patients.

Patients And Methods: A total of 50 patients with COPD and 19 healthy volunteers were enrolled in the study. EMPs (CD31+, CD62E+) and platelet-derived (CD61+, CD41+, CD42a+, PAC1+), red blood cell-derived (GlyA+) and leukocyte-derived (CD45+, CD13+, CD14+, CD56+) MPs were measured. Flow cytometry (FC) was performed on Beckman Coulter FC500 analyzer. MP reference gate was set using 0.3-0.5-0.9 µm microbeads with MP size gates of 0.5-1.0 µm.

Results: All the measured MPs were significantly (<0.001) higher in COPD patients than in the controls. Furthermore, CD62E+, CD41+, CD42a+ and CD14+ MP values were significantly (<0.001) increased in exacerbated COPD compared to stable COPD. These MPs showed significant (<0.001) inverse correlation with FEV/FVC, as well.

Conclusion: In this study, we describe a reliable flow cytometric assay for MP analysis that was successfully applied in COPD. Besides EMPs, COPD is accompanied by an increased concentration of various MPs in the systemic circulation; particularly, platelet- and monocyte-derived MPs seem to be important in exacerbation.

Citing Articles

Extracellular vesicles and COPD: foe or friend?.

Wu J, Ma Y, Chen Y J Nanobiotechnology. 2023; 21(1):147.

PMID: 37147634 PMC: 10161449. DOI: 10.1186/s12951-023-01911-5.

The potential applications of microparticles in the diagnosis, treatment, and prognosis of lung cancer.

Liu Y, Wang S, Xia H, Tan X, Song S, Zhang S J Transl Med. 2022; 20(1):404.

PMID: 36064415 PMC: 9444106. DOI: 10.1186/s12967-022-03599-x.

Serum-derived extracellular vesicles: Novel biomarkers reflecting the disease severity of COVID-19 patients.

Tertel T, Tomic S, dokic J, Radojevic D, Stevanovic D, Ilic N J Extracell Vesicles. 2022; 11(8):e12257.

PMID: 35979935 PMC: 9451525. DOI: 10.1002/jev2.12257.

Blood Cell-Derived Microvesicles in Hematological Diseases and beyond.

Georgatzakou H, Fortis S, Papageorgiou E, Antonelou M, Kriebardis A Biomolecules. 2022; 12(6).

PMID: 35740926 PMC: 9220817. DOI: 10.3390/biom12060803.

Extracellular vesicles and chronic obstructive pulmonary disease (COPD): a systematic review.

Gomez N, James V, Onion D, Fairclough L Respir Res. 2022; 23(1):82.

PMID: 35382831 PMC: 8985325. DOI: 10.1186/s12931-022-01984-0.

References

Yuana Y, Oosterkamp T, Bahatyrova S, Ashcroft B, Garcia Rodriguez P, Bertina R . Atomic force microscopy: a novel approach to the detection of nanosized blood microparticles. J Thromb Haemost. 2009; 8(2):315-23. DOI: 10.1111/j.1538-7836.2009.03654.x. View

Nielsen M, Beck-Nielsen H, Andersen M, Handberg A . A flow cytometric method for characterization of circulating cell-derived microparticles in plasma. J Extracell Vesicles. 2014; 3. PMC: 3916676. DOI: 10.3402/jev.v3.20795. View

Taylor Jr F, Toh C, Hoots W, Wada H, Levi M . Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2002; 86(5):1327-30. View

Gordon C, Gudi K, Krause A, Sackrowitz R, Harvey B, Strulovici-Barel Y . Circulating endothelial microparticles as a measure of early lung destruction in cigarette smokers. Am J Respir Crit Care Med. 2011; 184(2):224-32. PMC: 3172886. DOI: 10.1164/rccm.201012-2061OC. View

Piccin A, Murphy W, Smith O . Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 2006; 21(3):157-71. DOI: 10.1016/j.blre.2006.09.001. View

Dragovic R, Gardiner C, Brooks A, Tannetta D, Ferguson D, Hole P . Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis. Nanomedicine. 2011; 7(6):780-8. PMC: 3280380. DOI: 10.1016/j.nano.2011.04.003. View

Lacedonia D, Carpagnano G, Trotta T, Palladino G, Panaro M, Zoppo L . Microparticles in sputum of COPD patients: a potential biomarker of the disease?. Int J Chron Obstruct Pulmon Dis. 2016; 11:527-33. PMC: 4798204. DOI: 10.2147/COPD.S99547. View

Divo M, Cote C, de Torres J, Casanova C, Marin J, Pinto-Plata V . Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186(2):155-61. DOI: 10.1164/rccm.201201-0034OC. View

Tomaniak M, Gasecka A, Filipiak K . Cell-derived microvesicles in cardiovascular diseases and antiplatelet therapy monitoring - A lesson for future trials? Current evidence, recent progresses and perspectives of clinical application. Int J Cardiol. 2016; 226:93-102. DOI: 10.1016/j.ijcard.2016.10.007. View

10.

Poncelet P, Robert S, Bouriche T, Bez J, Lacroix R, Dignat-George F . Standardized counting of circulating platelet microparticles using currently available flow cytometers and scatter-based triggering: Forward or side scatter?. Cytometry A. 2015; 89(2):148-58. DOI: 10.1002/cyto.a.22685. View

11.

Shet A . Characterizing blood microparticles: technical aspects and challenges. Vasc Health Risk Manag. 2008; 4(4):769-74. PMC: 2597765. DOI: 10.2147/vhrm.s955. View

12.

Agusti A, Faner R . Systemic inflammation and comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2012; 9(2):43-6. DOI: 10.1513/pats.201108-050MS. View

13.

Picot J, Guerin C, Le Van Kim C, Boulanger C . Flow cytometry: retrospective, fundamentals and recent instrumentation. Cytotechnology. 2012; 64(2):109-30. PMC: 3279584. DOI: 10.1007/s10616-011-9415-0. View

14.

van der Pol E, van Gemert M, Sturk A, Nieuwland R, van Leeuwen T . Single vs. swarm detection of microparticles and exosomes by flow cytometry. J Thromb Haemost. 2012; 10(5):919-30. DOI: 10.1111/j.1538-7836.2012.04683.x. View

15.

Nieri D, Neri T, Petrini S, Vagaggini B, Paggiaro P, Celi A . Cell-derived microparticles and the lung. Eur Respir Rev. 2016; 25(141):266-77. PMC: 9487210. DOI: 10.1183/16000617.0009-2016. View

16.

Hugel B, Martinez M, Kunzelmann C, Freyssinet J . Membrane microparticles: two sides of the coin. Physiology (Bethesda). 2005; 20:22-7. DOI: 10.1152/physiol.00029.2004. View

17.

Thomashow M, Shimbo D, Parikh M, Hoffman E, Vogel-Claussen J, Hueper K . Endothelial microparticles in mild chronic obstructive pulmonary disease and emphysema. The Multi-Ethnic Study of Atherosclerosis Chronic Obstructive Pulmonary Disease study. Am J Respir Crit Care Med. 2013; 188(1):60-8. PMC: 3735242. DOI: 10.1164/rccm.201209-1697OC. View

18.

van der Pol E, Hoekstra A, Sturk A, Otto C, van Leeuwen T, Nieuwland R . Optical and non-optical methods for detection and characterization of microparticles and exosomes. J Thromb Haemost. 2010; 8(12):2596-607. DOI: 10.1111/j.1538-7836.2010.04074.x. View

19.

Jy W, Horstman L, Jimenez J, Ahn Y, Biro E, Nieuwland R . Measuring circulating cell-derived microparticles. J Thromb Haemost. 2004; 2(10):1842-51. DOI: 10.1111/j.1538-7836.2004.00936.x. View

20.

VanWijk M, VanBavel E, Sturk A, Nieuwland R . Microparticles in cardiovascular diseases. Cardiovasc Res. 2003; 59(2):277-87. DOI: 10.1016/s0008-6363(03)00367-5. View